Chronic rhinosinusitis without nasal polyps – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chronic rhinosinusitis without nasal polyps – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Itepekimab for Patients with Chronic Rhinosinusitis Without Nasal Polyps https://clinicaltrials.eu/trial/study-on-the-effects-of-itepekimab-for-patients-with-chronic-rhinosinusitis-without-nasal-polyps/ Wed, 29 Apr 2026 15:02:56 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-itepekimab-for-patients-with-chronic-rhinosinusitis-without-nasal-polyps/ This clinical trial is focused on studying a condition known as chronic rhinosinusitis without nasal polyps, which is a long-term inflammation of the sinuses that does not involve growths called polyps. The study will test a treatment called itepekimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body. Itepekimab is designed to target and block a protein called interleukin-33, which is involved in the inflammation process.

The purpose of this study is to evaluate how effective itepekimab is compared to a placebo in reducing sinus inflammation. Participants in the study will receive either itepekimab or a placebo through an injection under the skin. The study will last for a period of up to 24 weeks, during which participants will have regular check-ups to monitor their condition and any changes in their symptoms. The main focus will be on changes in the amount of sinus blockage, as seen on a CT scan, which is a type of imaging test that helps doctors see inside the body.

Throughout the study, participants will also be asked to keep track of their symptoms, such as nasal congestion, runny nose, facial pain, and loss of smell, using a daily electronic diary. The study will also monitor the safety and tolerability of itepekimab, looking for any side effects or reactions to the treatment. This research aims to provide more information on how well itepekimab works for people with chronic rhinosinusitis without nasal polyps and to ensure it is safe for use.

]]> Study on the Effect of Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps https://clinicaltrials.eu/trial/study-on-the-effect-of-dupilumab-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps/ Wed, 29 Apr 2026 14:29:39 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-dupilumab-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps/ This clinical trial is focused on studying the effects of a medication called Dupilumab on a condition known as Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Chronic rhinosinusitis is a long-term inflammation of the sinuses, and it can occur with or without nasal polyps, which are non-cancerous growths in the nasal passages. The study will explore how Dupilumab, which is administered as a solution for injection, affects the nasal lining in patients with CRSwNP.

The purpose of the study is to understand how Dupilumab impacts the nasal barrier function, which is the ability of the nasal lining to protect against harmful substances. Participants will receive Dupilumab treatment over a period of six months. The study will involve regular visits to monitor changes in the nasal barrier and other related factors. Some participants will receive a placebo for comparison.

Throughout the study, researchers will collect samples and data to assess changes in the nasal lining and other biological markers. This will help determine the effectiveness of Dupilumab in improving the condition of patients with CRSwNP. The study aims to provide valuable insights into the treatment of chronic rhinosinusitis and the role of Dupilumab in managing this condition.

]]>